30 results about "Plague vaccine" patented technology

Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH2-terminal β-strand of F1 of Yersinia pestis is transplanted to the COOH-terminus of F1 of Yersinia pestis and the NH2-terminus sequence flanking the β-strand of F1 of Yersinia pestis is duplicated to eliminate polymerization but to retain the T cell epitopes. The mutated F1 is fused to the V antigen of Yersinia pestis to thereby form a fusion protein F1mut-V mutant, which produces a completely soluble monomer. The fusion protein F1mut-V is then arrayed on phage T4 nanoparticles via a small outer capsid protein, Soc, from a T4 phage or a T4-related phage. Both the soluble and T4 decorated F1mut-V provided approximately 100% protection to mice and rats against pneumonic plague evoked by high doses of Yersinia pestis CO92.

Disclosed herein is a method of inducing an immunological response in a subject which comprises administering an immunogenic amount of a purified fusion protein comprising all or part of F1 antigen of Yersinia pestis fused to the amino terminus of all of V antigen of Yersinia pestis, Yersinia enterocolitica, or Yersinia pseudotuberculosis to the subject.

The invention discloses a plague bacteria protein with cellular immune protection function, an encoding gene and an application. The purpose is to provide the protein and the encoding gene which can stimulate T cell immune reaction during plague bacteria infection and immune processes and can generate cellular immune protection function, as well as the application in the preparation of plague vaccines. The experiments prove that the protein of the invention can stimulate T cell immune reaction during the infection and the immune processes of plague bacteria and can generate immune protection function. The protein or gene of the invention can be taken as an active ingredient for preparing the plague vaccines, and can enhance the immune protection effect and the immune protection region of the existing plague vaccines through mutual immunization or the combined immunization with the existing F1 and LcrV antigen or gene with immune protection function, or the preparation of a recombinant fusion multivalent subunit vaccine or DNA vaccine at the same time. The invention provides a new means for searching the protein of the plague bacteria with cellular immune protection function, which can play the important role in the prevention and the treatment of plague and have broad application prospect.

The invention provides a method for producing RHD (rabbit haemorrhagic disease) virus and vaccine by use of common easy-to-culture cell lines such as RK13, ST, VeroE6, BHK-21, PK-15, IBRS-2 and the like. The method comprises the following steps of: inoculating the RHD virus and adsorbing; adding an incubation agent and performing cell incubation; culturing cells with a cell maintenance medium to obtain RHD virus seeds for production; inoculating the RHD virus seeds and adsorbing; adding an incubation agent and performing cell incubation; re-adding a cell maintenance medium and culturing cells to obtain the RHD virus for vaccine preparation; adding an inactivator for inactivation; and then adding a veterinary-pharmaceutically acceptable vaccine adjuvant to obtain a finished product of the RHD vaccine. According to the method, the cell line for virus culture is a mature commercial cell line, the production technology is simple and stable, the operation is easy, the virus content is high, the inter-batch difference is little, the quality is easy to control, and the output and quality of the vaccine can be obviously improved. Through the invention, the produced RHD vaccine has high safety and high immunity, and realizes a complete immune protection effect against the RHD virulent attack.